These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 14770431)

  • 1. Survivin expression is associated with features of biologically aggressive prostate carcinoma.
    Shariat SF; Lotan Y; Saboorian H; Khoddami SM; Roehrborn CG; Slawin KM; Ashfaq R
    Cancer; 2004 Feb; 100(4):751-7. PubMed ID: 14770431
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Transforming growth factor-beta 1: comparative immunohistochemical localization in human primary and metastatic prostate cancer.
    Eastham JA; Truong LD; Rogers E; Kattan M; Flanders KC; Scardino PT; Thompson TC
    Lab Invest; 1995 Nov; 73(5):628-35. PubMed ID: 7474936
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tissue expression of transforming growth factor-beta1 and its receptors: correlation with pathologic features and biochemical progression in patients undergoing radical prostatectomy.
    Shariat SF; Menesses-Diaz A; Kim IY; Muramoto M; Wheeler TM; Slawin KM
    Urology; 2004 Jun; 63(6):1191-7. PubMed ID: 15183988
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expression of the survivin gene in prostate cancer: correlation with clinicopathological characteristics, proliferative activity and apoptosis.
    Kishi H; Igawa M; Kikuno N; Yoshino T; Urakami S; Shiina H
    J Urol; 2004 May; 171(5):1855-60. PubMed ID: 15076293
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Survivin expression in patients with non-muscle-invasive urothelial cell carcinoma of the bladder.
    Karam JA; Lotan Y; Ashfaq R; Sagalowsky AI; Shariat SF
    Urology; 2007 Sep; 70(3):482-6. PubMed ID: 17905101
    [TBL] [Abstract][Full Text] [Related]  

  • 6. TGF-beta receptor 2 downregulation in tumour-associated stroma worsens prognosis and high-grade tumours show more tumour-associated macrophages and lower TGF-beta1 expression in colon carcinoma: a retrospective study.
    Bacman D; Merkel S; Croner R; Papadopoulos T; Brueckl W; Dimmler A
    BMC Cancer; 2007 Aug; 7():156. PubMed ID: 17692120
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expression of survivin and apoptotic biomarkers in benign prostatic hyperplasia.
    Shariat SF; Ashfaq R; Roehrborn CG; Slawin KM; Lotan Y
    J Urol; 2005 Nov; 174(5):2046-50. PubMed ID: 16217391
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Up-regulation of Wnt-1 and beta-catenin production in patients with advanced metastatic prostate carcinoma: potential pathogenetic and prognostic implications.
    Chen G; Shukeir N; Potti A; Sircar K; Aprikian A; Goltzman D; Rabbani SA
    Cancer; 2004 Sep; 101(6):1345-56. PubMed ID: 15316903
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Survivin expression is associated with bladder cancer presence, stage, progression, and mortality.
    Shariat SF; Ashfaq R; Karakiewicz PI; Saeedi O; Sagalowsky AI; Lotan Y
    Cancer; 2007 Mar; 109(6):1106-13. PubMed ID: 17311310
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High expression levels of survivin protein independently predict a poor outcome for patients who undergo surgery for clear cell renal cell carcinoma.
    Parker AS; Kosari F; Lohse CM; Houston Thompson R; Kwon ED; Murphy L; Riehle DL; Blute ML; Leibovich BC; Vasmatzis G; Cheville JC
    Cancer; 2006 Jul; 107(1):37-45. PubMed ID: 16736510
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Levels of expression of p27KIP1 protein in human prostate and prostate cancer: an immunohistochemical analysis.
    Erdamar S; Yang G; Harper JW; Lu X; Kattan MW; Thompson TC; Wheeler TM
    Mod Pathol; 1999 Aug; 12(8):751-5. PubMed ID: 10463475
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Loss of p53 and c-myc overrepresentation in stage T(2-3)N(1-3)M(0) prostate cancer are potential markers for cancer progression.
    Qian J; Hirasawa K; Bostwick DG; Bergstralh EJ; Slezak JM; Anderl KL; Borell TJ; Lieber MM; Jenkins RB
    Mod Pathol; 2002 Jan; 15(1):35-44. PubMed ID: 11796839
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunohistochemical expression of transforming growth factor beta 1 and nm-23 H1 antioncogene in prostate cancer: divergent correlation with clinicopathological parameters.
    Stravodimos K; Constantinides C; Manousakas T; Pavlaki C; Pantazopoulos D; Giannopoulos A; Dimopoulos C
    Anticancer Res; 2000; 20(5C):3823-8. PubMed ID: 11268461
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nuclear factor-kappaB-mediated transforming growth factor-beta-induced expression of vimentin is an independent predictor of biochemical recurrence after radical prostatectomy.
    Zhang Q; Helfand BT; Jang TL; Zhu LJ; Chen L; Yang XJ; Kozlowski J; Smith N; Kundu SD; Yang G; Raji AA; Javonovic B; Pins M; Lindholm P; Guo Y; Catalona WJ; Lee C
    Clin Cancer Res; 2009 May; 15(10):3557-67. PubMed ID: 19447876
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The addition of interleukin-6 soluble receptor and transforming growth factor beta1 improves a preoperative nomogram for predicting biochemical progression in patients with clinically localized prostate cancer.
    Kattan MW; Shariat SF; Andrews B; Zhu K; Canto E; Matsumoto K; Muramoto M; Scardino PT; Ohori M; Wheeler TM; Slawin KM
    J Clin Oncol; 2003 Oct; 21(19):3573-9. PubMed ID: 12913106
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dedifferentiation in the metastatic progression of prostate carcinoma.
    Cheng L; Slezak J; Bergstralh EJ; Cheville JC; Sweat S; Zincke H; Bostwick DG
    Cancer; 1999 Aug; 86(4):657-63. PubMed ID: 10440694
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neuroendocrine cells in human prostate over-express the anti-apoptosis protein survivin.
    Xing N; Qian J; Bostwick D; Bergstralh E; Young CY
    Prostate; 2001 Jun; 48(1):7-15. PubMed ID: 11391682
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression of vascular endothelial growth factor receptor-3 (VEGFR-3) in human prostate.
    Li R; Younes M; Wheeler TM; Scardino P; Ohori M; Frolov A; Ayala G
    Prostate; 2004 Feb; 58(2):193-9. PubMed ID: 14716745
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expression of transforming growth factors in hepatocellular carcinoma and its relations with clinicopathological parameters and prognosis.
    Lu Y; Wu LQ; Li CS; Wang SG; Han B
    Hepatobiliary Pancreat Dis Int; 2008 Apr; 7(2):174-8. PubMed ID: 18397854
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Down-regulation of fragile histidine triad expression in prostate carcinoma.
    Fouts RL; Sandusky GE; Zhang S; Eckert GJ; Koch MO; Ulbright TM; Eble JN; Cheng L
    Cancer; 2003 Mar; 97(6):1447-52. PubMed ID: 12627509
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.